Clinical data.

ON, optic neuritis;*, relapses treated with high dose steroid pulse therapy; no included patient had an ON within 12 months prior to the beginning of the study;GLAT, glatiramer-acetate 20mg subcutaneous once daily; MITOX, mitoxantrone; IFN(a), interferon beta 1a intramuscularly once per week; IFN(b), interferon beta 1a (44μg) subcutaneous trice per week; IFN(c), interferon beta 1b (250μg) subcutaneous alternate day. Most importantly, the disease activity remained high in further follow-up with a median observation period of 22 ± 0.5 months [33]. However, no significant reduction of either the RNFL or the TMV could be found in follow-up [33; 36].1, discontinued (48mg mitoxantrone per m2 body surface); none, neither specific immunomodulatory or immunsuppressive therapy, drug holiday;2, drug withdrawal 12 months before OCT examination;3, drug withdrawal 6 months before OCT examination;4, drug withdrawal 20 months before OCT examination;5, high titres of anti-interferon autoantibodies, drug withdrawal 14 months before OCT examination;6, mitoxantrone cumulative dose 96mg per m2 body surface, drug withdrawal 10 months before OCT examination;7, mitoxantrone cumulative dose 92mg per m2 body surface, drug withdrawal 10 months before OCT examination;8, mitoxantrone cumulative dose 92mg per m2 body surface, drug withdrawal 26 months before OCT examination;9, mitoxantrone cumulative dose 108mg per m2 body surface, drug withdrawal 27 months before 1st OCT examination.Clinical data.